Q1 2023 Non-GAAP Operating Income

Q1 2023 Non-GAAP Summary $ billions, except EPS Q1 2023 Q1 2022 Change Revenues* 3.7 3.7 0% 1.8 2.0 (10%) Gross profit 49.1% 54.2% (5.2%) 0.8 1.0 (23%) Operating income 21.4% 27.7% (6.2%) EBITDA 0.9 1.1 (21%) Net income attributable to Teva 0.5 0.6 (25%) 0.40 0.55 (0.15) EPS ($) 1,128 million shares 1,112 million shares Free cash flow** 0.04 0.12 (65%) * Revenues are presented on a GAAP basis ** | 20 | Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets, net of cash used for capital investment. teva

View entire presentation